Document Detail

NOX inhibitors as a therapeutic strategy for stroke & neurodegenerative disease.
MedLine Citation:
PMID:  22204319     Owner:  NLM     Status:  Publisher    
NADPH oxidase was originally identified in immune cells as playing an important microbicidal role. In neurodegenerative and cerebrovascular diseases, inflammation is increasingly being recognized as contributing negatively to neurological outcome, with NADPH-oxidase as an important source of superoxide. Recently, several forms of this oxidase have been found in a variety of non-immune cells. Neuronal NADPH oxidase is thought to participate in long-term potentiation and intercellular signaling. However, excessive superoxide production is damaging and has been shown to play an important role in the progression of brain injury. NADPH oxidase is a multisubunit complex composed of membrane-associated gp91phox and p22phox subunits and cytosolic subunits, p47phox, p67phox, and p40phox and Rac. When NADPH oxidase is activated through phosphorylatoin of p47phox, cytosolic subunits translocate to the cell membrane and fuse with the catalytic subunit, gp91phox. The activated enzyme complex transports electrons to oxygen, thus producing the superoxide anion (O2●-), a precursor of reactive oxygen species. The advantage of a targeted NADPH oxidase inhibitor that would inhibit the production of superoxide non-phagocytic cells is clear. To date no such therapeutically viable inhibitor exists but recent research using current inhibitors has enhanced our knowledge of the role of NADPH oxidase in CNS diseases and provides impetus to develop a very specific, potent and safe NADPH oxidase inhibitor.
Belinda Cairns; Jong Youl Kim; Xian Nan Tang; Midori A Yenari
Related Documents :
17875649 - Mechanism by which exosites promote the inhibition of blood coagulation proteases by he...
17264079 - Structural and functional basis of cxcl12 (stromal cell-derived factor-1 alpha) binding...
1730729 - Conversion of antithrombin from an inhibitor of thrombin to a substrate with reduced he...
6790279 - Immunological evidence for a proteolytic cleavage at the active site of antithrombin in...
12717719 - Conformational behavior of chondroitin and chondroitin sulfate in relation to their phy...
11106599 - Heparan sulfate biosynthesis: a theoretical study of the initial sulfation step by n-de...
19791799 - Rnase h active site inhibitors of human immunodeficiency virus type 1 reverse transcrip...
16284619 - Conformational transition of initiation factor 2 from the gtp- to gdp-bound state visua...
9632679 - Unfolding of diphtheria toxin. identification of hydrophobic sites exposed on lowering ...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2011-12-29
Journal Detail:
Title:  Current drug targets     Volume:  -     ISSN:  1873-5592     ISO Abbreviation:  -     Publication Date:  2011 Dec 
Date Detail:
Created Date:  2011-12-29     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100960531     Medline TA:  Curr Drug Targets     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Department of Biological Sciences, Eck Institute for Global Health, University of Notre Dame, Notre Dame, IN 46556, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Estrogen, Neuroprotection and Neurogenesis after Ischemic Stroke.
Next Document:  Functional Roles of Synaptic and Extrasynaptic NMDA Receptors in Physiological and Pathological Neur...